Skip to Content

Workers’ Compensation Board

Search menu

The majority of online services should now be restored. Users may still experience lingering issues with some applications. Prior Authorization Request due dates have been extended to July 22nd. Digital Notices are now available.

Due to planned OnBoard maintenance occurring between 2:00 a.m. to 5:00 a.m. ET on Monday, July 22, 2024, and between 2:00 a.m. to 2:30 a.m. ET on Tuesday, July 23, 2024, email and text notifications may not be generated during this period. Please check your dashboards for prior authorization requests (PARs) and PAR responses submitted during this period. All other functionality will be working, including updates to the electronic case folders in eCase.

Subject Number 046-1112 Board Announces Revised NYS Workers’ Compensation Drug Formulary Regulation

Board Bulletins and Subject Numbers

October 17, 2018

The New York State Workers' Compensation Board (Board) has prepared a revision to the proposed NYS Workers' Compensation Drug Formulary (Formulary) announced in Subject Number 046-1012, Board Announces Draft Regulations for New York State Pharmacy Formulary on December 28, 2017. The proposed revision is in the October 17, 2018 State Register, and the Board will accept comments for 30 days. The revised proposed regulations are also available on the Board's website.

The Board substantially expanded the list of drugs on the Formulary, clarified the criteria for when certain drugs are on the Formulary and more fully defined the prior authorization process for drugs that are not listed on the Formulary.

The Board encourages the public, injured workers, employers, self-insured employers, insurance carriers, third-party administrators, attorneys, medical providers, and labor and business organizations to provide comment. Please submit your comments on or before November 16, 2018, to regulations@wcb.ny.gov. The Board will evaluate all comments received and will consider necessary revisions as the process advances.

The Board is committed to the successful implementation of the Formulary.

We look forward to receiving your comments.

Clarissa M. Rodriguez
Chair